SCHEMBL2656924

SCHEMBL2656924

Cc1cnc(-c2ccccc2C(N)=O)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.51
ALOX5AP P20292 3/20 0.51
FEN1 P39748 3/20 0.51
CSNK1A1 P48729 1/20 0.45
TYRO3 Q06418 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
GRM5 P41594 1/20 0.42
PARP1 P09874 2/20 0.41
CTSA P10619 2/20 0.40
NUDT1 P36639 1/20 0.40
METAP2 P50579 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180415 0.85 LDHA (0.51) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL21590306 0.82 BCAT2 (0.58) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL27684371 0.81 BCAT2 (0.51) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL3529606 0.81 BCAT2 (0.51) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL27579956 0.77 NOTUM (0.39) ALOX5APFEN1NPC1RAB9AALDH1A1
SCHEMBL30810367 0.77 ALOX5AP (0.51) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL30544780 0.76 TGFBR1 (0.53) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL45147 0.75 BCAT2 (0.53) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL30521876 0.75 BCAT2 (0.53) BCAT2ALOX5APFEN1CSNK1A1TYRO3
SCHEMBL31227852 0.75 BCAT2 (0.53) BCAT2ALOX5APFEN1CSNK1A1TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086964-A2 BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK Astra Zeneca AB (SE) 2009-08-12 EP claimed
WO-2008050101-A2 BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK ASTRAZENECA AB (SE) 2008-05-02 WO claimed
EP-2086964-A2 BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK Astra Zeneca AB (SE) 2009-08-12 EP disclosed
WO-2008050101-A2 BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK ASTRAZENECA AB (SE) 2008-05-02 WO disclosed
EP-1902052-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES AstraZeneca AB (SE) 2008-03-26 EP disclosed
CN-101018773-A Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2007-08-15 CN disclosed
WO-2007007041-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed